Botulinum toxin - OBIGEN PHARMA
Alternative Names: OBI 858Latest Information Update: 07 Apr 2026
At a glance
- Originator OBI Pharma
- Developer OBI Pharma; OBIGEN PHARMA
- Class Antispasmodics; Bacterial proteins; Bacterial toxins; Muscle relaxants; Skin disorder therapies; Urologics
- Mechanism of Action Acetylcholine inhibitors; Glutamate antagonists; Neuromuscular blocking agents
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase III Glabellar lines
- Discontinued Migraine
Most Recent Events
- 07 Apr 2026 Phase-II clinical trials in Glabellar lines in Taiwan (Parenteral) prior to April 2026
- 07 Apr 2026 Phase-III clinical trials in Glabellar lines in Taiwan (Parenteral) prior to April 2026
- 07 Apr 2026 OBIGEN PHARMA initiates a phase III trial in Glabellar lines in Taiwan (Parenteral) prior to April 2026